These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 26234904)
41. A novel class of antagonists for the FFAs receptor GPR40. Hu H; He LY; Gong Z; Li N; Lu YN; Zhai QW; Liu H; Jiang HL; Zhu WL; Wang HY Biochem Biophys Res Commun; 2009 Dec; 390(3):557-63. PubMed ID: 19818732 [TBL] [Abstract][Full Text] [Related]
42. Synthesis and pharmacological profile of a new selective G protein-coupled receptor 119 agonist; 6-((2-fluoro-3-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)propyl)amino)-2,3-dihydro-1H-inden-1-one. Sakairi M; Kogami M; Torii M; Makino M; Kataoka D; Okamoto R; Miyazawa T; Inoue M; Takahashi N; Harada S; Watanabe N Chem Pharm Bull (Tokyo); 2012; 60(9):1093-5. PubMed ID: 22976315 [TBL] [Abstract][Full Text] [Related]
43. Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles. Wang Y; Liu JJ; Dransfield PJ; Zhu L; Wang Z; Du X; Jiao X; Su Y; Li AR; Brown SP; Kasparian A; Vimolratana M; Yu M; Pattaropong V; Houze JB; Swaminath G; Tran T; Nguyen K; Guo Q; Zhang J; Zhuang R; Li F; Miao L; Bartberger MD; Correll TL; Chow D; Wong S; Luo J; Lin DC; Medina JC ACS Med Chem Lett; 2013 Jun; 4(6):551-5. PubMed ID: 24900707 [TBL] [Abstract][Full Text] [Related]
44. Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-Fluorination. Huang H; Meegalla SK; Lanter JC; Winters MP; Zhao S; Littrell J; Qi J; Rady B; Lee PS; Liu J; Martin T; Lam WW; Xu F; Lim HK; Wilde T; Silva J; Otieno M; Pocai A; Player MR ACS Med Chem Lett; 2019 Jan; 10(1):16-21. PubMed ID: 30655940 [TBL] [Abstract][Full Text] [Related]
45. Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists. Zhou C; Tang C; Chang E; Ge M; Lin S; Cline E; Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger J; Howard AD; Thornberry N; Mills SG; Yang L Bioorg Med Chem Lett; 2010 Feb; 20(3):1298-301. PubMed ID: 20064714 [TBL] [Abstract][Full Text] [Related]
46. Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates. Brown SP; Dransfield P; Vimolratana M; Zhu L; Luo J; Zhang J; Jiao X; Pattaropong V; Wong S; Zhuang R; Swaminath G; Houze JB; Lin DC ACS Med Chem Lett; 2018 Jul; 9(7):757-760. PubMed ID: 30034614 [TBL] [Abstract][Full Text] [Related]
47. Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes. Toda N; Hao X; Ogawa Y; Oda K; Yu M; Fu Z; Chen Y; Kim Y; Lizarzaburu M; Lively S; Lawlis S; Murakoshi M; Nara F; Watanabe N; Reagan JD; Tian H; Fu A; Motani A; Liu Q; Lin YJ; Zhuang R; Xiong Y; Fan P; Medina J; Li L; Izumi M; Okuyama R; Shibuya S ACS Med Chem Lett; 2013 Aug; 4(8):790-4. PubMed ID: 24900747 [TBL] [Abstract][Full Text] [Related]
49. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models. Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688 [TBL] [Abstract][Full Text] [Related]
50. Discovery of the imidazole-derived GPR40 agonist AM-3189. Ma Z; Lin DC; Sharma R; Liu J; Zhu L; Li AR; Kohn T; Wang Y; Liu JJ; Bartberger MD; Medina JC; Zhuang R; Li F; Zhang J; Luo J; Wong S; Tonn GR; Houze JB Bioorg Med Chem Lett; 2016 Jan; 26(1):15-20. PubMed ID: 26620255 [TBL] [Abstract][Full Text] [Related]
51. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus. Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065 [TBL] [Abstract][Full Text] [Related]
52. Catalytic Enantioselective Carbon-Oxygen Bond Formation: Phosphine-Catalyzed Synthesis of Benzylic Ethers via the Oxidation of Benzylic C-H Bonds. Ziegler DT; Fu GC J Am Chem Soc; 2016 Sep; 138(37):12069-72. PubMed ID: 27618638 [TBL] [Abstract][Full Text] [Related]
53. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist. Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144 [TBL] [Abstract][Full Text] [Related]
54. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists. Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985 [TBL] [Abstract][Full Text] [Related]
55. Modulating GPR40: therapeutic promise and potential in diabetes. Poitout V; Lin DC Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395 [TBL] [Abstract][Full Text] [Related]
56. Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558. Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Kimura T; Toda N Bioorg Med Chem; 2015 Sep; 23(17):5546-65. PubMed ID: 26234904 [TBL] [Abstract][Full Text] [Related]
57. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371 [TBL] [Abstract][Full Text] [Related]